<SEC-DOCUMENT>0001140361-18-045429.txt : 20181220
<SEC-HEADER>0001140361-18-045429.hdr.sgml : 20181220
<ACCEPTANCE-DATETIME>20181220090724
ACCESSION NUMBER:		0001140361-18-045429
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20181220
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181220
DATE AS OF CHANGE:		20181220

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aquestive Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001398733
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				208623253
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38599
		FILM NUMBER:		181244758

	BUSINESS ADDRESS:	
		STREET 1:		30 TECHNOLOGY DRIVE
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059
		BUSINESS PHONE:		908-941-1900

	MAIL ADDRESS:	
		STREET 1:		30 TECHNOLOGY DRIVE
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MonoSol Rx, Inc.
		DATE OF NAME CHANGE:	20070507
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>8-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using EDGARfilings PROfile 5.1.0.0
         Copyright 1995 - 2018 Broadridge -->
  </head>
<body text="#000000" bgcolor="#ffffff" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
  <div>
    <div>
      <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 14pt; font-weight: bold;">
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; font-size: 14pt;"><font style="font-family: &quot;Times New Roman&quot;; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</font></div>
      <div style="text-align: center; font-size: 12pt;"><font style="font-family: &quot;Times New Roman&quot;; font-weight: bold;">Washington, DC 20549</font></div>
      <div style="text-align: center; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;; font-weight: bold;"> <br>
        </font></div>
      <div>
        <div>
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      </div>
      <div style="text-align: center; font-size: 18pt;"><font style="font-family: &quot;Times New Roman&quot;; font-weight: bold;">FORM 8-K</font></div>
      <div style="text-align: center; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;; font-weight: bold;"> <br>
        </font></div>
      <div>
        <div>
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      </div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">CURRENT REPORT</font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> <br>
        </font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">PURSUANT TO SECTION 13 OR 15(d) OF THE</font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">SECURITIES EXCHANGE ACT OF 1934</font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> <br>
        </font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Date of Report (Date of earliest event reported): December 20, 2018</font></div>
      <div>
        <div><br>
        </div>
      </div>
      <div style="text-align: center;">
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"><font style="font-size: 24pt; font-family: &quot;Times New Roman&quot;;
          font-weight: bold;">Aquestive Therapeutics, Inc.</font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(Exact name of Registrant as specified in its charter)</font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> <br>
        </font></div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> </font>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse;" id="z85e9c462494f4d6f83b3ba03f792ff22">

          <tr>
            <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Delaware</font></div>
            </td>
            <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">001-38599</font></div>
            </td>
            <td style="width: 32.62%; vertical-align: top;">
              <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">82-3827296</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(State or Other Jurisdiction of Incorporation or Organization)</font></div>
            </td>
            <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(Commission File Number)</font></div>
            </td>
            <td style="width: 32.62%; vertical-align: top;">
              <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(I.R.S. Employer Identification No.)</font></div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">30 Technology Drive</font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Warren, NJ 07059</font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(908) 941-1900</font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#8217;s Principal Executive Offices)</font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> <br>
        </font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Not Applicable</font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(Former name or former address, if changed since last report)</font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> <br>
        </font></div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> </font>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
          following provisions:</font></div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> </font><br>
      </div>
      <div style="text-align: left;">
        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" class="DSPFListTable" id="z80550a7873914a218da737c8d65c45ab">

              <tr>
                <td style="width: 18pt; vertical-align: top;"><font style="font-size: 10pt; font-family: 'Times New Roman';">&#9744;</font></td>
                <td style="width: auto; vertical-align: top; text-align: left;">
                  <div><font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></font></div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> </font><br>
      </div>
      <div style="text-align: left;">
        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" class="DSPFListTable" id="z00d8a4792daf4c93ad3dd03c1b9bcb62">

              <tr>
                <td style="width: 18pt; vertical-align: top; align: right;"><font style="font-size: 10pt; font-family: 'Times New Roman';">&#9744;</font></td>
                <td style="width: auto; vertical-align: top; text-align: left;">
                  <div><font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)</font></font></div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> </font><br>
      </div>
      <div style="text-align: left;">
        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" class="DSPFListTable" id="z1131f20e351d446ab07a3cf8db481e3c">

              <tr>
                <td style="width: 18pt; vertical-align: top; align: right;"><font style="font-size: 10pt; font-family: 'Times New Roman';">&#9744;</font></td>
                <td style="width: auto; vertical-align: top; text-align: left;">
                  <div><font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></font></div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> </font><br>
      </div>
      <div style="text-align: left;">
        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" class="DSPFListTable" id="zf9a1ffe1938946828347fc8c00899d11">

              <tr>
                <td style="width: 18pt; vertical-align: top; align: right;"><font style="font-size: 10pt; font-family: 'Times New Roman';">&#9744;</font></td>
                <td style="width: auto; vertical-align: top; text-align: left;">
                  <div><font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></font></div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> </font><br>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Emerging growth company&#160; &#160;&#160; &#9746;</font></div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> </font><br>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
          revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <font style="font-size: 10pt; font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></font></div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Segoe UI Symbol', sans-serif;"> <br>
          </font></font></div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Segoe UI Symbol', sans-serif;"> </font></font>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left;">
        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" class="DSPFListTable" id="ze002b90ef81840a1985ab8b8a3969d45">

              <tr>
                <td style="width: 54pt; vertical-align: top;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Item 8.01</font></td>
                <td style="width: auto; vertical-align: top; text-align: left;">
                  <div><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Other Events.</font></div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> </font><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">On <font style="font-size: 10pt; font-family: 'Times New Roman';">December 20, 2018, </font>Aquestive Therapeutics, Inc. <font style="font-size: 10pt; font-family: 'Times New Roman';">issued a press release announcing an end of year business update</font>.&#160; A copy of such press release is attached as Exhibit 99.1 to this report and incorporated into this Item 8.01 by
          reference.</font></div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: &quot;Times New Roman&quot;;"> <br>
        </font></div>
      <div style="text-align: left;">
        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" class="DSPFListTable" id="zdb8a6971e3514badaa2ce29c034613df">

              <tr>
                <td style="width: 54pt; vertical-align: top;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Item 9.01</font></td>
                <td style="width: auto; vertical-align: top; text-align: left;">
                  <div><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Financial Statements and Exhibits</font></div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: &quot;Times New Roman&quot;;"> <br>
        </font></div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z31b0de3603bc4c648dca17cf7a926531" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

            <tr style="vertical-align: top;">
              <td style="width: 27pt;">&#160;</td>
              <td style="vertical-align: top; width: 18pt;">
                <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font></div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Exhibits.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> </font><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse;" id="z464563c3777b4716b88726de11911c62">

          <tr>
            <td style="width: 12%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Exhibit Number</font></div>
              </div>
            </td>
            <td style="width: 3%; vertical-align: bottom;">&#160;</td>
            <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); text-align: left;">
              <div><font style="font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Description</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 12%; vertical-align: top;">
              <div style="text-align: left;"><a href="ex99_1.htm"><font style="font-size: 10pt; font-family: 'Times New Roman';">99.1</font></a></div>
            </td>
            <td style="width: 3%; vertical-align: bottom;">&#160;</td>
            <td style="width: 85%; vertical-align: top;">
              <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Press Release, dated December 20, 2018</font></div>
            </td>
          </tr>

      </table>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> </font><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">SIGNATURE</font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> <br>
        </font></div>
      <div style="text-align: justify; text-indent: 24.5pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be
          signed on its behalf by the undersigned hereunto duly authorized.</font></div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> </font><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%; border-collapse: collapse;" id="z4d187ef4b219456da2a401fcf585b5ee">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: left; text-indent: -12pt; margin-left: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Dated: December 20, 2018</font></div>
            </td>
            <td colspan="2" rowspan="1" style="vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Aquestive Therapeutics, Inc.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: middle;">&#160;</td>
            <td colspan="2" rowspan="1" style="vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top; text-align: center;">
              <div style="text-align: left;"><font style="font-size: 10pt; font-family: &quot;Times New Roman&quot;;">By:</font></div>
            </td>
            <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">/s/ John T. Maxwell</font></div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 47%; vertical-align: top;">
              <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Name: John T. Maxwell</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: bottom;">&#160;</td>
            <td style="width: 47%; vertical-align: top;">
              <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Title: Chief Financial Officer</font></div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using EDGARfilings PROfile 5.1.0.0
         Copyright 1995 - 2018 Broadridge -->
  </head>
<body text="#000000" bgcolor="#ffffff" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
  <!--PROfilePageNumberReset%Num%1%%%-->
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit 99.1</div>
      <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br>
      </div>
      <div style="text-align: right;"><img width="128" height="42" src="image0.jpg"></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; font-weight: bold;"> <br>
        </font></div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; font-weight: bold;">Aquestive Therapeutics Provides End of Year Business Update, Including Progress of its Proprietary CNS Assets, Financial and
          Legal Matters</font></div>
      <div><br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z8e644bc74fa346cd932802c4aa6682e0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">

            <tr>
              <td style="width: 36pt; vertical-align: top; align: right;">
                <div style="text-align: left; margin-left: 18pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">&#8226;</font></div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Projects full year 2018 revenues over $67 million, exceeding expectations, and projects end of year cash and cash equivalents in the range of
                    $58 million to $60 million</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z64ebfc1c73384dd1bd10a857fa4cc1f0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">

            <tr>
              <td style="width: 36pt; vertical-align: top; align: right;">
                <div style="text-align: left; margin-left: 18pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">&#8226;</font></div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Delivers positive developments across Aquestive&#8217;s proprietary CNS portfolio, led by the commercial launch of Sympazan<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup> (clobazam)
                    Oral Film; expected NDA filing for Exservan<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup> (riluzole) Oral Film in January 2019; plan for rolling submission for Libervant<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup> (diazepam) Buccal Film to be submitted in January 2019</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z6a394d3b407c425c8b9608e13c4267bd" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">

            <tr>
              <td style="width: 36pt; vertical-align: top; align: right;">
                <div style="text-align: left; margin-left: 18pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">&#8226;</font></div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Anticipates branded Suboxone<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (buprenorphine / naloxone) Film in the U.S. and international, as well as any authorized generic in
                    the U.S., to be a significant revenue contributor to Aquestive through at least 2023</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z0f5b6fbb2b2f451183eb69320a58440f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">

            <tr>
              <td style="width: 36pt; vertical-align: top; align: right;">
                <div style="text-align: left; margin-left: 18pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">&#8226;</font></div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Hosts investment community conference call at 8:00 a.m. ET on December 20</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">WARREN, N.J., December 20, 2018 -- Aquestive Therapeutics, Inc. (NASDAQ: <u><font style="font-size: 10pt; font-family: 'Times New Roman';">AQST</font></u>),


          a specialty pharmaceutical company pharmaceutical company focused on identifying, developing, and commercializing differentiated products to solve therapeutic problems, is reporting positive developments across its business.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Sympazan<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup> Launch Propels Aquestive&#8217;s First Proprietary Franchise</font></div>
      <div><br>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">In November 2018, the company received approval from the U.S. Food and Drug Administration (FDA) for its first proprietary commercial product, Sympazan<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup>,
          for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older. Key pharmacokinetic (PK) data has been published in Epilepsia and presented at the American Epilepsy Society 2018 Annual Meeting in
          early December.</font></div>
      <div><br>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">With the product now in channel, sales and marketing plans are being executed to activate customer demand and new prescriptions. Aquestive&#8217;s commercial team
          of 50+ experienced professionals have already completed thousands of interactions with local healthcare providers, payers that cover approximately 280 million lives, and pharmacists in markets nationwide. The Company has also scheduled more than
          40 speaker programs through February, 2019. Important information for physicians is available at https://sympazanhcp.com, where healthcare professionals can access educational resources, request PharmFilm</font><font style="font-size: 10pt;
          font-family: 'Times New Roman';"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"><font style="font-size: 10pt; font-family: 'Times New Roman';">&#174;</font></sup> samples, and download copay cards that can assist LGS families.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">&#8220;The first scripts have been written and filled. We are very pleased with the reception of Sympazan in the market, and feel that our engagements with
          customers are positioning us well for the future launch of Libervant, when approved&#8221; said Ken Marshall, Chief Commercial Officer of Aquestive Therapeutics. &#8220;We look forward to building on our momentum in 2019.&#8221;</font></div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Regulatory Filings Are Advancing for Libervant<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup> and Exservan<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup> in 2019</font></div>
      <div><br>
      </div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Aquestive is developing diazepam buccal film (DBF or Libervant<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup>) for the treatment of seizure clusters in patients with refractory epilepsy.
          The company recently held a pre-NDA (New Drug Application) meeting with the FDA to review data and pharmacokinetic models generated thus far from multiple clinical studies. Based on the FDA&#8217;s feedback, the company is planning to complete a
          single-dose crossover study in a small number of epilepsy patients comparing DBF and Diastat dosing and, in parallel, advance plans for filing an NDA in 2019.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">&#8220;We are pleased with the feedback given by the FDA. We&#8217;ll develop the additional data as quickly as possible and we have a clear path to submission and
          approval,&#8221; said Keith J. Kendall, Chief Executive Officer of Aquestive Therapeutics. &#8220;Patients suffering from seizure clusters have been waiting a long time for an alternative to the current treatments available, and we are excited to bring these
          patients a medication that is fast-acting and easy to administer. Based on our data, we believe Libervant has the potential to significantly improve patient outcomes.&#8221;</font></div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: right;"><font id="DSPFPageNumber" style="font-family: Arial; font-size: 8pt; font-weight: normal; font-style: normal;">1</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: right;"><img src="image00001.jpg"></div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Libervant is a novel formulation of diazepam as a small, thin film strip for placement inside the cheek. Libervant leverages Aquestive&#8217;s proprietary
          PharmFilm&#174; technology, and is in development for the management of select patients with refractory epilepsy who require intermittent use of diazepam to control episodes of increased seizure activity or seizure clusters. Currently, the only
          product with FDA-approval for treatment is Diastat, a rectally-applied gel.</font></div>
      <div><br>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Aquestive is also planning to submit an NDA in January 2019 for riluzole oral film (ROF or Exservan<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup>). The company recently completed a
          swallowing safety study after receiving the FDA&#8217;s permission to shorten the study. The primary objective of the study was to evaluate the effect, if any, of investigational ROF on swallowing safety in subjects with amyotrophic lateral sclerosis
          (ALS).&#160; The study successfully met its primary endpoint and showed that Exservan has no adverse effect on swallowing safety in subjects with ALS.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Legal Proceedings and New Drivers of Suboxone&#174; Film Business</font></div>
      <div><br>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Aquestive and Indivior PLC (LON: INDV), are filing a petition with the U.S. Court of Appeals for the Federal Circuit (CAFC) for a rehearing by the original
          panel of judges, as well as a rehearing <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">en banc</font>, on the CAFC&#8217;s ruling to vacate the preliminary injunction (PI) granted by the U.S. District Court of New
          Jersey to enjoin Dr. Reddy's Laboratories ("DRL") from launching its generic buprenorphine/naloxone sublingual film product, which utilizes Aquestive&#8217;s PharmFilm&#174; technology. The PI will remain in place to enjoin DRL&#8217;s &#8220;at-risk&#8221; entry into the
          U.S. market until the CAFC rules on the joint petition. This decision will have no impact on the core Aquestive patent portfolio.</font></div>
      <div><br>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">&#8220;We will continue to work with Indivior to assert and protect our intellectual property embedded in SUBOXONE&#174; Sublingual Film against at-risk generic
          entrants,&#8221; said Mr. Kendall. &#8220;This will continue to be a significant source of revenue for Aquestive for the foreseeable future.&#8221;</font></div>
      <div><br>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Aquestive&#8217;s Suboxone revenues are driven by order volume from both branded and authorized generic products. Aquestive has a sole and exclusive worldwide
          manufacturing agreement with Indivior for both branded and authorized generic Suboxone, and will continue to fulfill non-U.S. orders, which also continue to grow as a percent of total Suboxone business.</font></div>
      <div><br>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Early Asset Pipeline Progressing</font></div>
      <div><br>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Several proprietary assets in early stages of development show promise for clinical advancement in 2019. Aquestive is continuing to optimize the
          formulations and advance proof-of-concept studies for AQST-108 (epinephrine) and AQST-305 (octreotide). Interactions with U.S. and ex-U.S. regulatory authorities and potential study investigators have provided valuable input into plans for
          clinical development. Additional clinical trials for both products will take place in 2019.</font></div>
      <div><br>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Solid Cash Position and Access to Non-Dilutive Capital Sources</font></div>
      <div><br>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Aquestive expects full-year 2018 revenues to be more than $67 million and expects to end 2018 with cash and cash equivalents in the range of $58 million to
          $60 million. The company plans to provide full year 2019 guidance in conjunction with the year-end conference call in March 2019.</font></div>
      <div><br>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">&#8220;With the cash we have on-hand, along with cash generated by our ongoing business, and additional options to monetize non-strategic, partnered product
          royalty streams, we have the resources we need to fulfill our business plans,&#8221; said Mr. Kendall.</font></div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: right;"><font id="DSPFPageNumber" style="font-family: Arial; font-size: 8pt; font-weight: normal; font-style: normal;">2</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: right;"><img src="image00001.jpg"></div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"> <br>
        </font></div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Investment Community Conference Call</font></div>
      <div><br>
      </div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">The Company will host an investment community conference call at 8:00 a.m. ET on Thursday, December 20, 2018. Investors and analysts may participate in
          the conference call by dialing (866) 417-5886 from the U.S. and (409) 217-8235 internationally, followed by the conference ID: 3376049.&#160; There will also be a simultaneous, live webcast available on the Investors section of the Company&#8217;s website
          at https://investors.aquestive.com/events-and-presentations. The webcast will be archived for 30 days.</font></div>
      <div><br>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">About Aquestive Therapeutics</font><font style="font-size: 10pt;
            font-family: 'Times New Roman';"><br>
          </font>Aquestive Therapeutics&#160;is a specialty pharmaceutical company committed to identifying, developing and commercializing differentiated products to address unmet medical needs.&#160;Aquestive Therapeutics&#160;has a late-stage proprietary product
          pipeline focused on the treatment of CNS diseases, and is working to advance orally-administered complex molecules that it believes can be alternatives to invasively-administered standard of care therapies. As the leader in developing and
          delivering drugs via its PharmFilm&#174; technology,&#160;Aquestive Therapeutics&#160;also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms.</font></div>
      <div><br>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">SYMPAZAN IMPORTANT SAFETY INFORMATION</font></div>
      <div style="background-color: #FFFFFF;">
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">BOXED WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS</font></div>
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.</font></div>
      </div>
      <div style="background-color: #FFFFFF;">
        <div>
          <table cellspacing="0" cellpadding="0" id="zb47ca76c33f843e8802e8de6bc5d5308" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">

              <tr>
                <td style="width: 18pt;">&#160;</td>
                <td style="width: 18pt; vertical-align: top; align: right;">
                  <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">&#8226;</font></div>
                </td>
                <td style="width: auto; vertical-align: top;">
                  <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate.</font></div>
                </td>
              </tr>

          </table>
        </div>
        <div>
          <table cellspacing="0" cellpadding="0" id="z30e1952c58f54cd3a2a9756bc979c105" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">

              <tr>
                <td style="width: 18pt;">&#160;</td>
                <td style="width: 18pt; vertical-align: top; align: right;">
                  <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">&#8226;</font></div>
                </td>
                <td style="width: auto; vertical-align: top;">
                  <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Limit dosages and durations to the minimum required.</font></div>
                </td>
              </tr>

          </table>
        </div>
        <div>
          <table cellspacing="0" cellpadding="0" id="z28c273c32ab046159062d2a560b9a266" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">

              <tr>
                <td style="width: 18pt;">&#160;</td>
                <td style="width: 18pt; vertical-align: top; align: right;">
                  <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">&#8226;</font></div>
                </td>
                <td style="width: auto; vertical-align: top;">
                  <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Follow patients for signs and symptoms of respiratory depression and sedation.</font></div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="background-color: #FFFFFF;">
        <div><br>
        </div>
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">CONTRAINDICATIONS</font></div>
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">SYMPAZAN is contraindicated in patients with a history of hypersensitivity to the drug or its ingredients. Hypersensitivity reactions have included
            serious dermatological reactions.</font></div>
        <div><br>
        </div>
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">WARNINGS AND PRECAUTIONS</font></div>
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Potentiation of Sedation from Concomitant Use with Central Nervous System (CNS) Depressants</font></div>
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">SYMPAZAN has a CNS depressant effect. Caution patients and/or caregivers against simultaneous use with other CNS depressants or alcohol as the effects of
            other CNS depressants or alcohol may be potentiated.</font></div>
        <div><br>
        </div>
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Somnolence or Sedation</font></div>
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">SYMPAZAN causes dose-related somnolence and sedation, which generally begins within the first month of treatment and may diminish with continued
            treatment. Monitor patients for somnolence and sedation, particularly with concomitant use of other CNS depressants. Caution patients against engaging in hazardous activities requiring mental alertness, i.e., operating dangerous machinery or
            motor vehicles, until the effect of SYMPAZAN is known.</font></div>
        <div><br>
        </div>
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Withdrawal Symptoms</font></div>
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Abrupt discontinuation of SYMPAZAN should be avoided. The risk of withdrawal symptoms is greater with higher doses. Withdraw SYMPAZAN gradually to
            minimize the risk of precipitating seizures, seizure exacerbation, or status epilepticus.</font></div>
        <div><br>
        </div>
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Serious Dermatological Reactions</font></div>
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Serious skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported with clobazam in both children
            and adults. Discontinue SYMPAZAN at the first sign of rash, unless the rash is clearly not drug-related.</font></div>
        <div><br>
        </div>
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Physical and Psychological Dependence</font></div>
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Patients with a history of substance abuse should be under careful surveillance when receiving SYMPAZAN.</font></div>
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
          </font></div>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: right;"><font id="DSPFPageNumber" style="font-family: Arial; font-size: 8pt; font-weight: normal; font-style: normal;">3</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: right;"><img src="image00001.jpg"></div>
      <div style="background-color: #FFFFFF;">
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
          </font></div>
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Suicidal Behavior and Ideation</font></div>
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">AEDs, including SYMPAZAN, increase the risk of suicidal thoughts or behavior in patients. Patients treated with SYMPAZAN should be monitored for the
            emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Inform patients, their caregivers, and families of the increased risk of suicidal thoughts and behaviors. Advise them to be
            alert for and report immediately to healthcare providers any emergence or worsening signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts of self-harm.</font></div>
        <div><br>
        </div>
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">ADVERSE REACTIONS</font></div>
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Adverse reactions (&#8805;10% and more frequently than placebo) included constipation, somnolence or sedation, pyrexia, lethargy, and drooling.</font></div>
        <div><br>
        </div>
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">DRUG INTERACTIONS</font></div>
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression. Limit dosage and duration of concomitant use of
            benzodiazepines and opioids and follow patients closely for respiratory depression and sedation. Concomitant use of SYMPAZAN with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence. Caution patients
            and/or caregivers against simultaneous use with other CNS depressants or alcohol, as effects of other CNS depressants or alcohol may be potentiated.</font></div>
        <div><br>
        </div>
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Hormonal contraceptives that are metabolized by CYP3A4; effectiveness may be diminished when given with SYMPAZAN. Additional non-hormonal forms of
            contraception are recommended when using SYMPAZAN. Dose adjustment may be necessary of drugs metabolized by CYP2D6 and of SYMPAZAN when co-administered with strong CYP2C19 inhibitors (e.g., fluconazole, fluvoxamine, ticlopidine).</font></div>
        <div><br>
        </div>
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">USE IN SPECIFIC POPULATIONS</font></div>
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Pregnancy and Lactation: SYMPAZAN may cause fetal harm and should only be used during pregnancy if the potential benefit justifies the potential risk to
            the fetus. Infants born to mothers who have taken benzodiazepines during the later stages of pregnancy can develop dependence, withdrawal syndrome and symptoms suggestive of floppy infant syndrome. SYMPAZAN is excreted in human milk. Because of
            the potential for serious adverse reactions in nursing infants from SYMPAZAN, discontinue nursing or discontinue the drug. Encourage patients to call the toll-free number 1-888-233-2334 to enroll in the Pregnancy Registry or visit <u><font style="font-size: 10pt; font-family: 'Times New Roman';">http://www.aedpregnancyregistry.org/</font>.</u></font></div>
      </div>
      <div><br>
      </div>
      <div style="background-color: #FFFFFF;">
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">You are encouraged to report negative side effects of prescription drugs to the FDA. Visit <u><font style="font-size: 10pt; font-family: 'Times New
                Roman';">www.fda.gov/medwatch</font></u>, or call 1-800-FDA-1088.</font></div>
        <div><br>
        </div>
        <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Please click here to see full <u><font style="font-size: 10pt; font-family: 'Times New Roman';">Prescribing Information</font></u>, including Boxed
            Warning.</font></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Forward-Looking Statement</font><font style="font-size: 10pt; font-family:
            'Times New Roman';"><br>
          </font>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "could," "estimate," "expects," "intend," "may," "plan," "potential,"
          "project," "will," "would," or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. Such statements include, but are not limited to, statements about regulatory approvals and pathways,
          clinical trial timing and plans, the achievement of clinical and commercial milestones, future financial and operating results, business strategies, market opportunities, financing, and other statements that are not historical facts.</font></div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: right;"><font id="DSPFPageNumber" style="font-family: Arial; font-size: 8pt; font-weight: normal; font-style: normal;">4</font></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: right;"><img src="image00001.jpg"></div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risks and uncertainties that could cause
          actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company's development work, including any delays or changes to the
          timing, cost and success of our product development activities and clinical trials; the risks of delays in FDA approval of our drug candidates or failure to receive approval; the risks inherent in commercializing a new product (including
          technology risks, financial risks, market risks and implementation risks and regulatory limitations); development of our sales and marketing capabilities; the rate and degree of market acceptance of our product candidates; the success of any
          competing products; the size and growth of our product markets; the effectiveness and safety of our product candidates; risks associated with intellectual property rights and infringement; unexpected patent developments; and other risks and
          uncertainties affecting the Company including those described in the "Risk Factors" section included in our Registration Statement on Form S-1 declared effective by the SEC on July 24, 2018. As with any pharmaceutical product candidate under
          development, there are significant risks with respect to the development, regulatory approval and commercialization of new products. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak
          only as of the date made. All subsequent forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. We assume no obligation to update our
          forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise, except as may be required under applicable law.</font></div>
      <div><br>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Media inquiries:<font style="font-size: 10pt; font-family: 'Times New Roman';"><br>
          </font>Christopher Hippolyte<font style="font-size: 10pt; font-family: 'Times New Roman';"><br>
          </font><u><font style="font-size: 10pt; font-family: 'Times New Roman';">christopher.hippolyte@syneoshealth.com</font></u><font style="font-size: 10pt; font-family: 'Times New Roman';"><br>
          </font>212-364-0458</font></div>
      <div><br>
      </div>
      <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Investor inquiries:<font style="font-size: 10pt; font-family: 'Times New Roman';"><br>
          </font>Stephanie Carrington<font style="font-size: 10pt; font-family: 'Times New Roman';"><br>
          </font><u><font style="font-size: 10pt; font-family: 'Times New Roman';">stephanie.carrington@icrinc.com</font></u><font style="font-size: 10pt; font-family: 'Times New Roman';"><br>
          </font>646-277-1282</font></div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <div id="DSPFPageNumberArea" style="text-align: right;"><font id="DSPFPageNumber" style="font-family: Arial; font-size: 8pt; font-weight: normal; font-style: normal;">5</font></div>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !X 7 # 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)* ^F<Y_2O'/#]SJMGKEM/H@D.I(Q,/EIO;..P^E>B?\)9\9/^HO_P" 0_\
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M',&GU?4)4'\ "KG\<5Z=X:\)Z+X2L/L>CV:P(>7?J[GU)[T <'^T)_R3E/\
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M51T% %FBBB@!LD:31M'(H='&&5AD$5X5X_\ AK/I$TNIZ1$TM@QW/$HRT/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
%HH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  K ((# 2(  A$! Q$!_\0
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M;7FH%X8U9"APH [,<56TOX%^';/5["\N]5\0ZI;Z?*)K2QO[XRP0N.A"X'3
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$0!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
